Hologic's CFO confirmed that Q2 fiscal 2025 results met financial commitments, with revenue and EPS at the high end of guidance. The company maintained its full-year revenue guidance, but the organic growth rate saw a slight tick down due to China headwinds being offset by favorable foreign exchange.
The full-year EPS guidance was lowered by $0.10, primarily due to an expected $20 million to $25 million quarterly impact from tariffs. These tariffs largely stem from manufacturing operations in Costa Rica, which produce surgical and breast interventional products.
Hologic anticipates a $5 million tariff impact in Q3, close to $20 million in Q4, with the full effect expected in Q1 fiscal 2026. The company is exploring mitigation strategies, including product flows, IP positioning, and supplier negotiations, while noting that USPSTF draft cervical cancer screening guidelines continue to support co-testing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.